Immobilized P2X2 purinergic receptor stationary phase for chromatographic determination of pharmacological properties and drug screening.
The purinergic receptor signaling system plays an important role in communication between cells in the nervous system and opens new opportunities for screening of potential drugs. Our objective was to explore the pharmacological properties and establish a new methodology for ligand screening for the P2X2 receptor, which has been developed by the combinatorial library approach Systematic Evolution of Ligands by Exponential enrichment (SELEX). To this end, membranes of 1321N1 cells stably transfected with rat P2X2 receptors were resuspended in 2% cholate detergent and subsequently coupled onto an immobilized artificial membrane (IAM). The IAM-cholate-P2X2 mixture was then dialyzed, centrifuged and packed into a FPLC column. Equilibrium binding to the receptor and competition between ATP and the purinergic antagonists suramin and 2'3'-O-(2,4,6-trinitrophenyl) adenosine 5'-triphosphate (TNP-ATP) were analyzed by a chromatographic assay using 32P alpha ATP as a radioligand. Our data indicate that suramin does not compete with ATP for the ligand binding site and TNP-ATP is a competitive antagonist, confirming previous studies [C.A. Trujillo, A.A. Nery, A.H. Martins, P. Majumder, F.A. Gonzalez, H. Ulrich, Biochemistry 45 (2006) 224-233]. In addition, we demonstrate that this assay can be used in in vitro selection procedures for RNA aptamers binding to P2X2 receptors. The results demonstrate that the receptor can be immobilized in a stable format and reused over an extended period of time, facilitating the exploration of ligand-receptor interactions and screening of combinatorial pools for possible ligands.
Trujillo
Cleber A
CA
Departamento de Bioquímica, Instituto de Química, Universidade de São Paulo, São Paulo 05508-900, Brazil.
Majumder
Paromita
P
Gonzalez
Fernando A
FA
Moaddel
Ruin
R
Ulrich
Henning
H
D000255:Adenosine Triphosphate / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D001254:Astrocytoma / Q000473:pathology; D001667:Binding, Competitive; D018929:Cell Culture Techniques; D045744:Cell Line, Tumor; D002846:Chromatography, Affinity / Q000379:methods*; D004353:Drug Evaluation, Preclinical; D005456:Fluorescent Dyes / Q000378:metabolism; D006801:Humans; D008024:Ligands; D008954:Models, Biological; D009474:Neurons / Q000187:drug effects; D018408:Patch-Clamp Techniques; D058919:Purinergic P2 Receptor Antagonists; D051381:Rats; D018048:Receptors, Purinergic P2 / Q000235:genetics / Q000378:metabolism*; D058476:Receptors, Purinergic P2X2; D011994:Recombinant Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism; D052156:SELEX Aptamer Technique; D013498:Suramin / Q000494:pharmacology*; D014162:Transfection
D005456:Fluorescent Dyes; D008024:Ligands; C546401:P2RX2 protein, human; C546403:P2rx2 protein, rat; D058919:Purinergic P2 Receptor Antagonists; D018048:Receptors, Purinergic P2; D058476:Receptors, Purinergic P2X2; D011994:Recombinant Proteins; D013498:Suramin; C045674:2',3'-O-(2,4,6-trinitro-cyclohexadienylidine)adenosine 5'-triphosphate; D000255:Adenosine Triphosphate